Pfizer Inc. $PFE Shares Bought by Valley Wealth Managers Inc.

Valley Wealth Managers Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,035,192 shares of the biopharmaceutical company’s stock after acquiring an additional 21,005 shares during the quarter. Pfizer makes up 1.5% of Valley Wealth Managers Inc.’s portfolio, making the stock its 18th biggest holding. Valley Wealth Managers Inc.’s holdings in Pfizer were worth $29,524,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. BlackRock Inc. grew its stake in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. State Street Corp raised its stake in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after buying an additional 3,999,646 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $1,049,602,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after buying an additional 293,029 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst support improved: JPMorgan raised its price target from $28 to $30 while maintaining a neutral rating, and Jefferies issued a buy rating. Cantor Fitzgerald also increased its target to $28, signaling some potential downside protection at current levels.
• Positive Sentiment: TUKYSA approval expands Pfizer’s oncology opportunity: The FDA approved TUKYSA in combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for certain patients with HER2-positive metastatic breast cancer. Moving the drug into an earlier line of treatment could broaden its commercial reach. FDA Backs Pfizer’s TUKYSA Combination
• Positive Sentiment: Pipeline progress adds longer-term support: Pfizer’s Phase 3 trial of tilrekimig, an asthma candidate, is advancing. Investors are also focused on oncology sales, biosimilars and the late-stage pipeline ahead of quarterly results. Tilrekimig Phase 3 Trial Update
• Positive Sentiment: Income and valuation appeal remain catalysts: Pfizer’s dividend announcement, roughly 6% yield and valuation below many large pharmaceutical peers continue to attract income and value-oriented investors. The company also has a history of earnings beats, with its latest reported quarter exceeding consensus estimates for both earnings and revenue.
• Neutral Sentiment: Investor attention is elevated: Pfizer was among heavily searched stocks, while broader biotechnology interest was helped by Moderna’s Nasdaq-100 inclusion. These factors may increase trading activity but do not directly change Pfizer’s fundamentals.
• Negative Sentiment: High yield raises risk concerns: Commentary warns that Pfizer’s unusually large dividend yield may reflect investor doubts about earnings, cash flow, debt and the durability of the payout. Sluggish revenue growth, a thin net margin and relatively low return on equity reinforce those concerns. Pfizer Dividend Yield Analysis
• Negative Sentiment: Cost-cutting highlights operational pressure: Pfizer plans to close a penicillin unit in Italy and eliminate about 330 jobs, underscoring efforts to improve efficiency amid a challenging growth outlook. Pfizer Italy Penicillin Unit Closure

Analyst Ratings Changes

Several brokerages recently weighed in on PFE. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Scotiabank increased their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.72.

Pfizer Stock Performance

PFE opened at $28.27 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average price is $27.68 and its two-hundred day moving average price is $26.50. The firm has a market capitalization of $161.14 billion, a P/E ratio of 37.20, a price-to-earnings-growth ratio of 1.87 and a beta of 0.32. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $29.21.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the company earned $0.78 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s dividend payout ratio is 226.32%.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.